New restrictions enforced on MS drug daclizumab
Posted: Fri Jan 12, 2018 2:53 am
Back in July 2017, the Medical and Healthcare products Regulatory Agency (MHRA) highlighted restrictions on the use of daclizumab (Zinbryta) for relapsing remitting multiple sclerosis (RRMS) during an urgent EU review into the risk of severe liver injury... Read more - http://www.ms-uk.org/new-restrictions-e ... daclizumab
